Photodynamic Therapy with Verteporfin in Treatment of Myopic Neovascular Choroideal Membranes
Authors:
D. Vysloužilová; P. Kolář; V. Matušková
Authors‘ workplace:
Oční klinika LF MU a FN Brno Bohunice, přednosta prof. MUDr. E. Vlková, CSc
Published in:
Čes. a slov. Oftal., 68, 2012, No. 4, p. 131-134
Category:
Original Article
Overview
The aim of this study was to evaluate efficiency and long-term stabilization effect in patients with classic type of myopic choroidal neovascular membrane (CNV), treated with photodynamic therapy (PDT) with verteporfin (Visudyne – Novartis AG, Basel, Switzerland). We have verified the efficiency of photodynamic therapy with verteporfin in group of 51 eyes (17 men, 34 women), mean age 49,5 years with subfoveal localized predominantly classic neovascular membranes in pathologic myopia. The average follow up period was 23,7 months (± 2,3 month). Patients underwent during follow-up period 1 to 3 sessions of photodynamic therapy (PDT average number 1,25 sessions). The average best corrected visual acuity (BCVA) before treatment was 0,302 (0,65 logMAR) and the average BCVA at the end of follow up was 0,356 (0,46 log MAR). The improvement of best corrected visual acuity up to 5 letters on ETDRS (Early Treatment Diabetic Retinopathy Study) charts was observed in 23% of patients at the end of follow up.
Key words:
photodynamic therapy, chorioideal neovascularisation, pathologic myopia, fluorescein angiography, OCT
Sources
1. Alliston, BA, Protchard, PH, Levy, JG.: Evidence for low-density lipoprotein receptor-mediated uptake of benzoporphyrin derivate. Br J Cancer, 1994; 69: 833–839.
2. Bandello F, Lanzetta P, Battaglia Parodi M, Ranam Poginuz Z, Saviano S, Ravalico G.: Photodynamic therapy of subfoveolar recurrences after laser photocoagulation of extrafoveolar chorioidal neovascularisation in pathologic myopia. Graefes Arch Clin Exp Ophthalmol, 2003; 241: 567–570.
3. Blinder KJ, Blumenkranz MS, Bressler NM, Bressler SB, Donato G, Lewis H, et al.: Verteporfin therapy in subfoveal choroidal neovascularisation in pathologic myopia: 2-year result of a randomised clinical trial – VIP report no.3. Ophthalmology 2003; 110: 667–673.
4. Guidelines for using verteporfin (Visudyne) in fotodynamic therapy for choroidal neovascularisation due to age related macular degeneration and other causes: update. Retina 2005; 25: 119–134.
5. Hotchkiss ML, Fine SL.: Pathologic myopia and chorioideal neovascularisation. Am J Ophthalmology 1981, 91, p. 177–183.
6. Kolář P. a kol.: Věkem podmíněná makulární degenerace. Praha, Grada, 2008.
7. Soubrane, G., Kuhn, D., Coscas, G.: Indications for photodynamic therapy in age-related macular degeneration. J Fr Ophthalmol, 2004; 27: 79–80.
8. Yoshida T, Ohno-Matsui K, Yasuzumi K, Kojima A, Shimada N, Futagami S, et al.: Myopic choroidal neovascularisation; Ten years follow up. Ophthalmology, 2003; 110: 1297–305.
Labels
OphthalmologyArticle was published in
Czech and Slovak Ophthalmology
2012 Issue 4
Most read in this issue
- Sub-internal Limiting Membrane Haemorrhage Treated by Pars Plana Vitrectomy
- Perforated Punctum Plugs in Treatment Lacrimal Punctal Stenosis
- Efficacy and Tolerability of Preservative-free Tafluprost 0.0015 % in the Treatment of Glaucoma and Ocular Hypertension
- Extrascleral Overgrowth of Malignant Choroidal Melanoma after Endoresection